Compare CLPR & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLPR | COCH |
|---|---|---|
| Founded | 2015 | 1995 |
| Country | United States | United States |
| Employees | N/A | 47 |
| Industry | Real Estate Investment Trusts | Blank Checks |
| Sector | Real Estate | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.3M | 49.7M |
| IPO Year | 2015 | N/A |
| Metric | CLPR | COCH |
|---|---|---|
| Price | $3.11 | $0.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 72.8K | ★ 117.8K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | ★ 10.73% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $109,997,000.00 | N/A |
| Revenue This Year | N/A | $1.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.82 | N/A |
| 52 Week Low | $2.83 | $0.36 |
| 52 Week High | $4.61 | $1.89 |
| Indicator | CLPR | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 46.97 | 42.40 |
| Support Level | $2.88 | $0.36 |
| Resistance Level | $3.28 | $0.74 |
| Average True Range (ATR) | 0.14 | 0.04 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 25.81 | 18.20 |
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.